RANDOMIZED STUDY OF PHASE III WITH RADIOTHERAPY IN PATIENTS MASTECTOMIZED BY BREAST CANCER OF CLINICAL STAGE II, WITH ONE TO THREE POSITIVE GANGLES
Not Applicable
- Conditions
- -C50 Malignant neoplasm of breastMalignant neoplasm of breastC50
- Registration Number
- PER-076-03
- Lead Sponsor
- EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients should be women with breast adenocarcinoma,
histologically confirmed, with a primary tumor of <5 cm and 1-3 positive axillary lymph nodes. Patients with positive lymph nodes only by cytokeratin staining and negative with hematoxylin-eosin are not eligible.
Patients must not have received Trastuzumab previously.
Exclusion Criteria
underage
pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of radiotherapy in breast cancer patients with 1-3 positive lymph nodes post-mastectomy?
How does adjuvant radiotherapy compare to standard-of-care treatments for clinical stage II breast cancer with limited lymph node involvement?
Which biomarkers correlate with improved outcomes in breast cancer patients receiving radiotherapy after mastectomy for stage II disease?
What are the long-term adverse events associated with radiotherapy in stage II breast cancer patients with 1-3 positive lymph nodes?
Are there combination therapies or targeted agents that enhance radiotherapy efficacy in breast cancer with limited lymph node metastasis?